C-PQV4X-tosis
mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PQV4
C-PQV4C-PQV4mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
X-tosis states that Alzheimer’s and Parkinson’s diseases can be meaningfully treated by targeting mitochondrial dysfunction, specifically VDAC1 oligomerization, which it describes as a critical driver of cell death and inflammation in neurodegenerative disorders. The company presents its XTS compounds as a novel, research-based approach intended to protect neuronal health, optimize cellular function, halt disease progression, and improve patients’ quality of life worldwide.
SourceX-tosis presents itself as a precision-medicine platform company focused on preventing neuronal loss through first-in-class mitochondrial therapeutics. The company states that modulating VDAC1 can restore mitochondrial function, reduce inflammation, prevent apoptosis and neuronal death, and thereby offer a disease-modifying treatment approach for Alzheimer's disease, Parkinson's disease, ALS, and related neurodegenerative conditions, with precision biomarkers used to guide patient selection, treatment, and monitoring.
SourceNo company beliefs, mission, or theory statements are visible in the provided 2024-11-09 Wayback snapshot text; the visible content appears to be only Internet Archive capture metadata rather than the company’s site content.
Source